DDrare: Database of Drug Development for Rare Diseases

15. 封入体筋炎
［臨床試験数：39，薬物数：32（DrugBank：11），標的遺伝子数：11，標的パスウェイ数：119］

Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ABC008; ARIMOCLOMOL; Alemtuzumab; Alemtuzumab (Campath); Anakinra; Arimoclomol; Arimoclomol citrate; BOTULINUM TOXIN TYPE A; BRX-345; BYM338; BYM338 (Bimagrumab); BYM338/bimagrumab; Bimagrumab; Botulinum toxin type A; Care as usual; Etanercept; FLEBOGAMMA 5%; Gamma Globulin; Immunoglobulins, normal human, for intravascular adm.; Natalizumab; Null; Other: Blood-flow restricted training; Phenylbutyrate; Phenylbutyrate Oral Tablet; Pioglitazone; RAAV1.CMV.huFollistatin344; REGN2477+REGN1033; Rapamycin; SIVASTIN; Simvastatin; Sivastin; Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02573467 (ClinicalTrials.gov)	November 2, 2015	9/7/2015	An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203	Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis	Sporadic Inclusion Body Myositis	Drug: Bimagrumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	36 Years	N/A	All	211	Phase 3	United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom
2	NCT02250443 (ClinicalTrials.gov)	March 11, 2014	20/3/2014	Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis	An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis	Sporadic Inclusion Body Myositis (sIBM)	Drug: BYM338 (Bimagrumab)	Novartis Pharmaceuticals	NULL	Completed	40 Years	75 Years	All	10	Phase 2;Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02573467
(ClinicalTrials.gov)

November 2, 2015

9/7/2015

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis

Drug: Bimagrumab;Drug: Placebo

Novartis Pharmaceuticals

NULL

Completed

36 Years

N/A

All

211

Phase 3

United States;Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom

NCT02250443
(ClinicalTrials.gov)

March 11, 2014

20/3/2014

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis (sIBM)

Drug: BYM338 (Bimagrumab)

Novartis Pharmaceuticals

NULL

Completed

40 Years

75 Years

All

Phase 2;Phase 3

United States